Figure 5

Quantitative determination of Arachidonic acid (AA) in ipsilateral brain tissues on the 1^st, 3^rd, 7^th, 14^th and 21^st days after TBI or sham injury or TBI gavaged with oral XFZY.

(A) GC-MS m/z of AA after MeOx-TMS derivatization is 67, 73, 75, 79, 91 and 117. The top diagram shows the mass spectrum of AA in a brain sample and the bottom diagram shows the mass spectrum of standard AA. (B) GC-MS TICs of AA after MeOx-TMS derivatization. (C) Brain tissue concentration of AA on the 1^st, 3^rd, 7^th, 14^th and 21^st days after injury. The contents of AA were significantly increased in the Vehicle group compared with the sham group from the 1^st to the 14^th days post-injury, whereas treatment with 9 g/kg XFZY significantly reduced the increased AA levels compared with the Vehicle group on the 1^st, 3^rd, 7^th and 14^th days. Treatment with 18 g/kg XFZY significantly reduced the increased levels of AA compared with the Vehicle group on the 1^st, 3^rd and 7^th days. On the 3^rd day, treatment with 9 g/kg XFZY significantly reduced the levels of AA in ipsilateral brain tissue compared with 18 g/kg XFZY group (n = 8/group). All of the data were analyzed by two-way ANOVA and are presented as the mean ± SEM. *p < 0.05, ^#p < 0.01 vs. the Vehicle group. ^Δp < 0.05 vs. the 9 g/kg XFZY group.